ctDNA MRD monitoring during neoadjuvant treatment for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort of 119 adults (age 18–75) with borderline resectable, high‑risk resectable, or locally advanced pancreatic adenocarcinoma who are planned for neoadjuvant therapy at Ruijin Hospital. Participants will receive standard-of-care neoadjuvant treatment determined by a multidisciplinary team while undergoing serial blood draws to measure ctDNA-based MRD at defined time points. The study will correlate MRD status changes with surgical outcomes (including R0 resection rates) and survival endpoints (DFS and OS) and explore whether MRD dynamics can inform optimal neoadjuvant therapy duration. Patients with distant metastasis, prior anticancer therapy, or concurrent malignancies are excluded, and follow-up spans the planned recruitment and observation period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects meeting ALL of the following criteria will be enrolled:

  1. Age and Gender :Aged 18-75 years, regardless of gender.
  2. Diagnosis and Disease Stage :

     Pathologically confirmed pancreatic cancer, meeting NCCN guideline criteria for:

     A. High-risk resectable (meeting ≥1 criterion):
     1. Luminal stenosis of the portal vein or superior mesenteric vein on imaging;
     2. Radiographic stage T≥3 or N≥1;
     3. Serum CA19-9 ≥1000 U/mL (after resolution of jaundice);
     4. Confirmed regional lymph node metastasis;
     5. Significant weight loss (\>10% baseline) or severe pain requiring opioids.

     B. Borderline resectable :
     1. Tumor involving the common hepatic artery without celiac axis contact;
     2. Tumor contact with SMA ≤180°.

     C. Locally advanced (unresectable):
     1. Tumor encasement (\>180°) of the SMA, celiac axis, or common hepatic artery;
     2. Unreconstructable involvement of SMV/portal vein;
     3. No distant metastasis.
  3. Treatment Suitability :Deemed suitable for neoadjuvant therapy after multidisciplinary team (MDT) discussion .
  4. Performance Status :ECOG (Eastern Cooperative Oncology Group) performance status ≤1 .
  5. Life Expectancy :Estimated survival ≥6 months.
  6. Organ Function :No severe cardiac, hepatic, or renal dysfunction, including:

     ALT/AST ≤3×ULN (upper limit of normal); Serum creatinine ≤1.5×ULN .
  7. Informed Consent :Signed written informed consent voluntarily provided.

Exclusion Criteria:

* Subjects meeting ANY of the following criteria will be excluded:

  1. Distant Metastasis Radiographically confirmed distant metastatic lesions.
  2. Prior Anti-Tumor Therapy History of any prior anti-tumor treatment, including:

     Systemic chemotherapy Radiotherapy Interventional therapy Immunotherapy Targeted therapy Anti-tumor traditional Chinese medicine therapy.
  3. Concurrent Malignancy Diagnosis of other active malignancies.
  4. Pregnancy or Lactation Female subjects who are pregnant or breastfeeding.
  5. Drug Allergy Hypersensitivity to any agents in the guideline-recommended first-line neoadjuvant regimen .
  6. Transplantation History Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation .
  7. Immunodeficiency Disorders Congenital or acquired immunodeficiency, including:

Human Immunodeficiency Virus (HIV) infection;

Active Hepatitis B :

HBsAg-positive andHBV-DNA ≥10,000 copies/mL (≥2,000 IU/mL) at screening;

Active Hepatitis C :

HCV-Ab-positive andHCV-RNA positive at screening; Co-infection with HBV and HC

Where it's running

• Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
  Shanghai, China Recruiting
• Ruijin hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Baiyong Shen, MD
• Email: lfl12522@rjh.com
• Phone: +86 021-64370045-678805

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant treatment for borderline resectable pancreatic cancer

  This study is testing a new combination of chemotherapy, immunotherapy, and radiation before surgery to see if it can help people with borderline resectable pancreatic cancer live longer and have better treatment results.

  Recruiting at 3 sites Phase 1/2 Amsterdam UMC, location VUmc · Amsterdam and 3 other locations · NCT06384560

• HRS-4642 plus nimotuzumab and chemotherapy for borderline resectable pancreatic cancer with KRAS G12D

  This Phase II trial will test whether adding HRS-4642 and nimotuzumab to gemcitabine and albumin-bound paclitaxel helps adults with borderline resectable pancreatic cancer that has a KRAS G12D mutation.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07240766

• Using NALIRIFOX for treating resectable pancreatic cancer before and after surgery

  This study is testing if a new combination treatment called NALIRIFOX can help people with resectable pancreatic cancer have better surgery results and live longer.

  Recruiting at 9 sites Phase 2 Taichung Veterans General Hospital · Kaohsiung City and 8 other locations · NCT06816914

• PTM-101 treatment for pancreatic cancer

  This study is testing a new treatment called PTM-101 combined with chemotherapy to see if it can help people with certain types of pancreatic cancer who haven't had treatment before.

  Recruiting at 9 sites Phase 1 PanTher Therapeutics · Newport Beach, California and 8 other locations · NCT06673017

• Evaluating the effects of oxaliplatin on liver and nerve toxicity in cancer patients

  This study is testing how the cancer drug oxaliplatin affects the liver and nerves in patients with pancreatic and esophageal cancers to help make chemotherapy safer and more effective.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT06649474

• Neoadjuvant chemotherapy for resectable pancreatic cancer

  This study is testing a combination of three chemotherapy drugs to see if it helps people with resectable pancreatic cancer get better before surgery.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia and 1 other locations · NCT06423326

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.